Chen Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chen Tan has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Juan R. Cubillos-Ruiz
Weill Cornell Medicine
21 shared publications - Alexander Emmanuelli
Associate Professor of Microbiology and Immunology Well Cornell Medicine New York NY
20 shared publications - Chang-Suk Chae
Associate Professor of Microbiology and Immunology Well Cornell Medicine New York NY
20 shared publications - Deepika Awasthi
Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY 10065, USA
20 shared publications - Tito Alejandro Sandoval
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA
20 shared publications - Anna Vähärautio
Research Program in Systems Oncology, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S3 contains all statistically significant DEGs from RNAseq data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S3 contains all statistically significant DEGs from RNAseq data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S4 describes the organoids used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S4 describes the organoids used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis of peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination with cisplatin. Figure S3. (a-f) Wild-type female mice were implanted with ID8-Defb29/Vegfa tumors and treated as described in Fig 2 d. Figure S4. (a) Representative images of NKp46 staining on the entire omentum. Figure S5. (a) MTT assays for ID8-Defb29/Vegfa, PPNM, and MP cells treated with different concentrations of deferiprone for 12, 24, and 48 hours. Figure S6. (a) Human ovarian cancer cell lines were treated with deferiprone for 48 hours and expression of the indicated genes was analyzed by qRT-PCR. Colors indicate fold change (FC) upon deferiprone treatment compared with vehicle control. Figure S7. (a-b) Mitochondrial iron was traced using mito-ferrogreen in iron-overloaded ID8-Defb29/Vegfa cells that were exposed to deferiprone (100 µM) or vehicle control. Figure S8. (a) Schematic representation of treatment regimens under IFNAR1 blockade related to Fig. 6 a-c.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis of peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination with cisplatin. Figure S3. (a-f) Wild-type female mice were implanted with ID8-Defb29/Vegfa tumors and treated as described in Fig 2 d. Figure S4. (a) Representative images of NKp46 staining on the entire omentum. Figure S5. (a) MTT assays for ID8-Defb29/Vegfa, PPNM, and MP cells treated with different concentrations of deferiprone for 12, 24, and 48 hours. Figure S6. (a) Human ovarian cancer cell lines were treated with deferiprone for 48 hours and expression of the indicated genes was analyzed by qRT-PCR. Colors indicate fold change (FC) upon deferiprone treatment compared with vehicle control. Figure S7. (a-b) Mitochondrial iron was traced using mito-ferrogreen in iron-overloaded ID8-Defb29/Vegfa cells that were exposed to deferiprone (100 µM) or vehicle control. Figure S8. (a) Schematic representation of treatment regimens under IFNAR1 blockade related to Fig. 6 a-c.
- 29 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (822) , eady5288
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent and limiting side effect of paclitaxel treatment in patients with cancer. CIPN affects sensory neurons through neuroinflammatory mechanisms, but how immune cells sense and interpret systemic paclitaxel exposure during treatment is unclear. Here, we found that paclitaxel administration activated the endoplasmic reticulum (ER) stress sensor inositol-requiring enzyme 1α (IRE1α) in circulating and dorsal root ganglion–resident myeloid cells, engendering an inflammatory milieu that promotes CIPN. Mechanistically, paclitaxel induced the overproduction of mitochondria-derived reactive oxygen species (ROS) that provoked ER stress and IRE1α hyperactivation in macrophages. This process reprogrammed macrophages toward an inflammatory state characterized by IRE1α-dependent production of TNF-α, IL-1β, PGE 2 , IL-6, IL-5, GM-CSF, MCP-1, and MIP-2. Ablation of IRE1α in leukocytes, or treatment with a selective IRE1α pharmacological inhibitor, prevented dorsal root ganglion neuroinflammation and CIPN-related pain behaviors in mice. Furthermore, the development and severity of CIPN in patients with gynecological cancer were associated with the status of IRE1α activation in their circulating leukocytes. Our study uncovers leukocyte-intrinsic IRE1α as a key mediator of CIPN and suggests that targeting its dysregulated activation could help mitigate CIPN in patients with cancer who are receiving paclitaxel.
- 29 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (822) , eady5288
Leukocyte-intrinsic ER stress responses contribute to chemotherapy-induced peripheral neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent and limiting side effect of paclitaxel treatment in patients with cancer. CIPN affects sensory neurons through neuroinflammatory mechanisms, but how immune cells sense and interpret systemic paclitaxel exposure during treatment is unclear. Here, we found that paclitaxel administration activated the endoplasmic reticulum (ER) stress sensor inositol-requiring enzyme 1α (IRE1α) in circulating and dorsal root ganglion–resident myeloid cells, engendering an inflammatory milieu that promotes CIPN. Mechanistically, paclitaxel induced the overproduction of mitochondria-derived reactive oxygen species (ROS) that provoked ER stress and IRE1α hyperactivation in macrophages. This process reprogrammed macrophages toward an inflammatory state characterized by IRE1α-dependent production of TNF-α, IL-1β, PGE 2 , IL-6, IL-5, GM-CSF, MCP-1, and MIP-2. Ablation of IRE1α in leukocytes, or treatment with a selective IRE1α pharmacological inhibitor, prevented dorsal root ganglion neuroinflammation and CIPN-related pain behaviors in mice. Furthermore, the development and severity of CIPN in patients with gynecological cancer were associated with the status of IRE1α activation in their circulating leukocytes. Our study uncovers leukocyte-intrinsic IRE1α as a key mediator of CIPN and suggests that targeting its dysregulated activation could help mitigate CIPN in patients with cancer who are receiving paclitaxel.
- Open Access
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- Open Access
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- Open Access
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study